Actelion Tracleer Registry Would Issue Liver Monitoring Reminders
Executive Summary
Actelion is planning a Tracleer registry that would send monthly liver monitoring reminders to patients taking the pulmonary hypertension therapy, the company told FDA's Cardiovascular & Renal Drugs Advisory Committee Aug. 10.
You may also be interested in...
Actelion Will Launch Tracleer Through Closed Distribution System
Actelion's launch of the pulmonary hypertension drug Tracleer will include converting 200 patients in an ongoing, open-label trial to its closed commercial distribution system, the company told analysts Nov. 21
Actelion Will Launch Tracleer Through Closed Distribution System
Actelion's launch of the pulmonary hypertension drug Tracleer will include converting 200 patients in an ongoing, open-label trial to its closed commercial distribution system, the company told analysts Nov. 21
United Therapeutics Remodulin Efficacy Shown By Secondary Data - Cmte.
United Therapeutics' Remodulin efficacy may be based on secondary measures rather than primary endpoints because the pulmonary arterial hypertension therapy will be prescribed for a small population, FDA's Cardiovascular & Renal Drugs Advisory Committee agreed at its Aug. 9 meeting.